These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12205498)

  • 21. Monoclonal antibody successes in the clinic.
    Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC
    Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pitfalls in the development of biologic therapy.
    Maini RN; Feldmann M
    Nat Clin Pract Rheumatol; 2007 Jan; 3(1):1. PubMed ID: 17202998
    [No Abstract]   [Full Text] [Related]  

  • 23. Great company, bad stock.
    Jacobs T
    Nat Biotechnol; 2005 Feb; 23(2):173. PubMed ID: 15696142
    [No Abstract]   [Full Text] [Related]  

  • 24. Monoclonals expand into neural disorders.
    Vastag B
    Nat Biotechnol; 2006 Jun; 24(6):595-6. PubMed ID: 16763572
    [No Abstract]   [Full Text] [Related]  

  • 25. A special biotech speculation.
    Jacobs T
    Nat Biotechnol; 2006 Jun; 24(6):622. PubMed ID: 16763586
    [No Abstract]   [Full Text] [Related]  

  • 26. Monoclonal antibodies: production, uses and side effects.
    Cowden J; Parker SK
    Pediatr Infect Dis J; 2006 Jun; 25(6):553-5. PubMed ID: 16732156
    [No Abstract]   [Full Text] [Related]  

  • 27. Hidden in plain view.
    Jacobs T
    Nat Biotechnol; 2003 Jun; 21(6):603. PubMed ID: 12776141
    [No Abstract]   [Full Text] [Related]  

  • 28. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

  • 29. CD20 blockers eye crowded rheumatology market.
    Mack GS
    Nat Biotechnol; 2008 Oct; 26(10):1053-4. PubMed ID: 18846053
    [No Abstract]   [Full Text] [Related]  

  • 30. mAbs: a business perspective.
    Scolnik PA
    MAbs; 2009; 1(2):179-84. PubMed ID: 20061824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Any diamonds in the diagnostic coal?
    Jacobs T
    Nat Biotechnol; 2006 Aug; 24(8):930. PubMed ID: 16900133
    [No Abstract]   [Full Text] [Related]  

  • 32. On the Lucentis controversy.
    Christie S
    Health Serv J; 2008 Feb; ():17. PubMed ID: 18390246
    [No Abstract]   [Full Text] [Related]  

  • 33. Fortune 1,000 ranked within industries. 48. Pharmaceuticals.
    Fortune; 2004 Apr; 149(7):F59-F60. PubMed ID: 15077541
    [No Abstract]   [Full Text] [Related]  

  • 34. Fortune 1,000. Ranked within industries. 8. Chemicals.
    Fortune; 2004 Apr; 149(7):F46. PubMed ID: 15077536
    [No Abstract]   [Full Text] [Related]  

  • 35. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 36. Trials and error.
    Jacobs T
    Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
    [No Abstract]   [Full Text] [Related]  

  • 37. The new world disorder.
    Stires D
    Fortune; 2002 Dec; 146(12):62-4, 68, 70 passim. PubMed ID: 12500480
    [No Abstract]   [Full Text] [Related]  

  • 38. New challenges to medicare beneficiary access to mAbs.
    Cohen J; Wilson A
    MAbs; 2009; 1(1):56-66. PubMed ID: 20046575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biotech industry struggles with generics approval.
    Knight J
    Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
    [No Abstract]   [Full Text] [Related]  

  • 40. A new approach to drug development.
    Frangioni JV
    N Engl J Med; 2006 Nov; 355(19):2046; author reply 2046. PubMed ID: 17099947
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.